UTILITY PATENT APPLICATION TRANSMITTAL

Docket No.: P-204.00CON

Page 1 of 2

Title: ALPHA 1-ANTITRYPSIN PREPARATION AND METHOD FOR THE PRODUCTION THEREOF

Express Mail Label No.: EL800474590US

(Under 37 C.F.R. §1.53(b))

	APPLICATION ELEMENTS	ADDRESS TO: Assistant Commissioner for Patents				
IN	VENTORS: Erwin Mattes, H. Peter Matthiessen	Box Patent Application Washington, D.C. 20231				
1.	X Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	10. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations				
2.	X Specification [Total Pages 27]	Preliminary Amendment filed 12/10/99 and reliminaryAmendment filed herewith.				
3.	Drawing(s) (35 USC §113) [Total Pages (Fig. 1)]	12. X Return Receipt Postcard (MPEP 503)				
4.	X Signed Declaration [Total Pages 2]	13. Small Entity Statement(s)				
and that had the	a. Newly executed (original or copy)	14. Certified Copy of Priority Documents (s)				
	b. X Copy from a prior application (37 CFR §1.63(d))	15a. Cancel in the application original claimsbefore calculating the filing fee				
	i. (Note Box 5 below) DELETION OF INVENTOR(S)	15b. X Amend the specification by inserting before the first line the sentence: —This is a X Continuation,				
	Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)	Divisional, Continuation-in-part, of application 09/445,590, filed 03/13/00. 15c. X I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number 09/445,590, filed 03/13/00 and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001				
5.						
⇒ 5.	Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied					
ž	under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.					
6.	Nucleotide and/or Amino Acid Sequence Submission	of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any				
a. b. c.	Computer Readable Copy Paper Copy (identical to computer copy) Statement Verifiying identify of above copies	Patent issuing thereon.				
7.	Assignment Papers (cover sheet & document(s))	15d Other				
8.	Attorney					
9	English Translation Document					
1	16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:					
	X Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09/445,590.					

THE PARTY OF THE P

UTILITY PATENT APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: P-204.00CON

Page 2 of 2

Title: ALPHA 1-ANTITRYPSIN PREPARATION AND METHOD FOR THE PRODUCTION THEREOF

Express Mail Label No.: EL800474590US

	(Olidei 37 C.I. IX. §1.35(b))				
CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	10-20 =	0	X \$ 18 =	\$.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	1-3 =	0	X \$ 80 =	\$.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 270 =	\$.00
45010				BASIC FEE (37 CFR §1.16(a))	\$710.00
	Application of the state of the			TOTAL =	\$710.00
The Commission	oner is hereby authorized ng the pendency of the ap	plication, to Dep	osit Account No. 0)2 -1437 (Docket P-20	any other fees 4.00CON).

(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- Fees required under 37 CFR §1.16
- Fees required under 37 CFR §1.17
- Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350			
SIGNATURE	C. Jeghanni			
DATE	September 24, 2001			

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation P.O. Box 15210 Irvine, California 92614

Telephone: (949) 250-6827

Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL800474590US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on September 24, 2001

Diane Branham